204 related articles for article (PubMed ID: 4521481)
1. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
Schwartz HS
Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
[No Abstract] [Full Text] [Related]
2. DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
Schwartz HS
Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):51-64. PubMed ID: 1124321
[TBL] [Abstract][Full Text] [Related]
3. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
Johnson RK; Ovejera AA; Goldin A
Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
[No Abstract] [Full Text] [Related]
4. Letter: DNA complexes of daunorubicin (NSC-8215) and adriamycin (NSC-123127).
Trouet A; de Duve C
Cancer Chemother Rep; 1975; 59(2 Pt 1):260. PubMed ID: 1149004
[No Abstract] [Full Text] [Related]
5. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
Marks TA; Venditti JM
Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
[TBL] [Abstract][Full Text] [Related]
6. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.
Schwartz HS; Grindey GB
Cancer Res; 1973 Aug; 33(8):1837-44. PubMed ID: 4720795
[No Abstract] [Full Text] [Related]
7. Another hypothesis concerning the antitumor activity and cardiotoxicity of daunorubicin (NSC-82151) and adriamycin (NSC-123127).
Wheeler DM
Cancer Chemother Rep; 1975; 59(2 Pt 1):258-9. PubMed ID: 1149002
[No Abstract] [Full Text] [Related]
8. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
[TBL] [Abstract][Full Text] [Related]
9. Adriamycin (NSC-123127) and its analogs.
Henry DW
Cancer Chemother Rep 2; 1974 Dec; 4(4):5-9. PubMed ID: 4451911
[No Abstract] [Full Text] [Related]
10. Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.
Silvestrini R; Lenaz L; Di Fronzo G; Sanfilippo O
Cancer Res; 1973 Nov; 33(11):2954-8. PubMed ID: 4748447
[No Abstract] [Full Text] [Related]
11. Actinomycin D effects on nucleic acids during tumor regression.
Schwartz HS; Sodergren JE
Cancer Res; 1968 Mar; 28(3):445-51. PubMed ID: 5238558
[No Abstract] [Full Text] [Related]
12. Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.
Sirotnak FM; Donsbach RC
Cancer Res; 1973 Jun; 33(6):1290-4. PubMed ID: 4718678
[No Abstract] [Full Text] [Related]
13. [Possibility of utilizing lymphatic leukemia L1210 as a first screening model in the primary selection of new antitumor antibiotics].
Shorin VA; Bazhanov VS
Antibiotiki; 1974 Aug; 19(8):679-84. PubMed ID: 4455117
[No Abstract] [Full Text] [Related]
14. [Selective tumour chemotherapy using oncobiograms (author's transl)].
Volm M; Kaufmann M; Wayss K; Goerttler K; Mattern J
Dtsch Med Wochenschr; 1974 Jan; 99(2):38-43. PubMed ID: 4129485
[No Abstract] [Full Text] [Related]
15. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo.
Mizuno NS; Humphrey EW
Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462
[No Abstract] [Full Text] [Related]
16. [Possibilities and limits of pre-therapeutic neoplasm sensitivity cytostatics tests under short-term conditions].
Volm M; Kaufmann M; Mattern J; Wayss K
Schweiz Med Wochenschr; 1975 Jan; 105(3):74-82. PubMed ID: 1121657
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
Dombernowsky P; Nissen NI
Eur J Cancer (1965); 1976 Mar; 12(3):181-8. PubMed ID: 939236
[No Abstract] [Full Text] [Related]
18. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
Deprez-de Campeneere D; Baurain R; Trouet A
Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
Meriwether WD; Bachur NR
Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814
[No Abstract] [Full Text] [Related]
20. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
Ohnuma T; Elias F; Holland JF; Henderson E
Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
